SciSparc Ltd. is a clinical stage pharmaceutical company, which focuses on creating and enhancing a portfolio of technologies and assets based on cannabinoid pharmaceuticals. The firm is engaged in drug development programs based on repurposing a cannabinoid (Dronabinol): THX-110 for the treatment of Tourette syndrome (TS), for the treatment of Obstructive Sleep Apnea (OSA), and the treatment of Pain; THX-130 for the treatment of Mild Cognitive Impairment (MCI) and Traumatic Brain Injury (TBI); THX-150 for the treatment of infectious diseases; and THX-160 for the treatment of pain.
Follow-Up Questions
Who is the CEO of Scisparc Ltd?
Mr. Amitay Weiss is the Chief Executive Officer of Scisparc Ltd, joining the firm since 2020.
What is the price performance of SPRC stock?
The current price of SPRC is $3.76, it has decreased 1.57% in the last trading day.
What are the primary business themes or industries for Scisparc Ltd?
Scisparc Ltd belongs to Pharmaceuticals industry and the sector is Health Care
